alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 104 studies in Current Alzheimer Research (page 1 of 5) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study

✓ Peer-reviewed alzhub usefulness score 77 out of 100. Current Alzheimer research 2018-01-01

No significant difference was seen in cognitive and functional decline between early and delayed treatment groups. 4 key findings →

Design: clinical trial Participants: 85 Evidence: high

Full summary, score breakdown and related studies → Original source

Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients

✓ Peer-reviewed alzhub usefulness score 77 out of 100. Current Alzheimer research 2009-02

AD patients aged 50-85 years were randomized to open-label treatment with oral rivastigmine, donepezil or galantamine for 13 weeks. 5 key findings →

Design: open-label trial Participants: 63 Evidence: high

Full summary, score breakdown and related studies → Original source

Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study

✓ Peer-reviewed alzhub usefulness score 74 out of 100. Current Alzheimer research 2007-02-01

In this 10-week, double-blind, fixed-dose study, elderly institutionalized patients with dementia and agitation were randomized (3:3:2) to quetiapine 200mg/day, 100mg/day, or placebo. 2 key findings →

Participants: 117 Evidence: high

Full summary, score breakdown and related studies → Original source

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Current Alzheimer research 2008-02-01

In this trial, memantine did not show an advantage over placebo based on protocol-specified primary or secondary analyses in patients with mild to moderate AD on stable ChEI regimens. 2 key findings →

Participants: 433 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Current Alzheimer research 2009-08-01

The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a multi-center study assessing neuroimaging in diagnosis and longitudinal monitoring. 4 key findings →

Design: longitudinal study Participants: 339 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Current Alzheimer research 2005-12-01

The trial did not show efficacy of GbE, however, the lack of decline of the placebo patients may have compromised the sensitivity of the trial to detect a treatment effect. 3 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Current Alzheimer research 2011-08-01

Two phase 3 studies evaluated the efficacy and safety of rosiglitazone (RSG), a type 2 diabetes treatment, in an extended release (RSG XR) form as adjunctive therapy to ongoing acetylcholine esterase inhibitor (AChEI) treatment in AD (REFLECT-2, adjunctive to donepezil; REFLECT-3, to any AChEI). 4 key findings →

Design: clinical trial Participants: 1,496 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Current Alzheimer research 2018-01-01

Transition probabilities from normal cognition through AD severity states are important for understanding patient progression across the AD spectrum. 1 key finding →

Design: longitudinal study Participants: 18,103 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Physical Activity as a Moderator of Alzheimer Pathology: A Systematic Review of Observational Studies

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Current Alzheimer research 2019-01-01

The quality of included studies with only a few longitudinal studies, limits the conclusions which may be drawn from the present findings especially regarding the biomarkers other than hippocampal volume. 4 key findings →

Design: systematic review Participants: 40 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Cognitive changes preceding clinical symptom onset of mild cognitive impairment and relationship to ApoE genotype

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Current Alzheimer research 2014-01-01

Cognitive changes in normal individuals who will subsequently decline may be observed at least 6.5 years prior to symptom onset. 1 key finding →

Design: longitudinal study Participants: 208 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The effects of cognitive speed of processing training among older adults with psychometrically- defined mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Current Alzheimer research 2012-11-01

Despite the growing interest in cognitive training programs as a potential non-pharmacological approach to slowing cognitive decline in mild cognitive impairment (MCI), there has been little research on the differential effectiveness of training among subtypes of MCI (i.e., amnestic, single non-amnestic, and multi-domain). 2 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source

Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Current Alzheimer research 2005-07-01

Cholesterol-induced production of amyloid beta (Abeta) as a putative neurotoxin in Alzheimer's disease (AD), along with epidemiological evidence, suggests that statin drugs may provide benefit in treatment of the disorder. 5 key findings →

Participants: 98 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Current Alzheimer research 2013-09-01

As neuroinflammation is an early event in the pathogenesis of Alzheimer' s disease, new selective antiinflammatory drugs could lead to promising preventive strategies. 3 key findings →

Design: randomized controlled trial Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The Minority Aging Research Study: ongoing efforts to obtain brain donation in African Americans without dementia

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Current Alzheimer research 2012-07-01

The Minority Aging Research Study (MARS) is a longitudinal, epidemiologic cohort study of decline in cognitive function and risk of Alzheimer's disease (AD) in older African Americans, with brain donation after death added as an optional component for those willing to consider organ donation. 1 key finding →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Brain Aging in African-Americans: The Atherosclerosis Risk in Communities (ARIC) Experience

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Current Alzheimer research 2015-01-01

Reported rates of dementia differ by race, although most studies have not focused on carefully measured outcomes, confounding by education or other demographic factors, nor have they studied other outcomes other than dementia. 1 key finding →

Participants: 15,792 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Blood Biomarkers Discriminate Cerebral Amyloid Status and Cognitive Diagnosis when Collected with ACD-A Anticoagulant

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Current Alzheimer research 2023

Plasma AB42/40 had the highest AUC (0.833, 95% C.I. 0.767-0.899) at a cut-point of 0.0706 for discriminating between the two cerebral amyloid groups (sensitivity 76%, specificity 78.5%). 5 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source

Screening for Genetic Mutations Associated with Early-Onset Alzheimer's Disease in Han Chinese

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Current Alzheimer research 2022

We identified 7 functional variants in APP/PSENs in 8 patients, including 1 APP mutation (p. Val715Met), 3 PSEN1 mutations (p. Phe177Ser; p. Arg377Met; p. Ile416Thr), and 3 PSEN2 mutations (p. Glu24Lys; p. Gly34Ser; p. Met239Thr). 5 key findings →

Participants: 34 Evidence: low

Full summary, score breakdown and related studies → Original source

Probiotic Supplementation in Patients with Alzheimer's Dementia - An Explorative Intervention Study

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Current Alzheimer research 2018-01-01

Dysbiosis of intestinal microbiota in the elderly can cause a leaky gut, which may result in silent systemic inflammation and promote neuroinflammation - a relevant pathomechanism in the early course of Alzheimer's disease. 4 key findings →

Participants: 18 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Vagus Nerve Stimulation in the Management of Neurodegenerative Diseases: A Systematic Review of Advances in Animal Research and Clinical Applications

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Current Alzheimer research 2026-01-01

Vagus Nerve Stimulation (VNS) shows neuroprotective and anti-inflammatory effects in animal models of Alzheimer's and Parkinson's disease, but clinical results remain inconsistent due to variability in treatment duration, outcome measures, and reliance on subjective assessments. 5 key findings →

Design: systematic review Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The Indiana Alzheimer Disease Center's Symposium on Mild Cognitive Impairment. Cognitive training in older adults: lessons from the ACTIVE Study

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Current Alzheimer research 2009-08-01

This paper is based on a presentation made during the Indiana Alzheimer Disease Center's Symposium on Mild Cognitive Impairment on April 19, 2008. 3 key findings →

Participants: 3,000 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed